title: [Research progress in metabolic and receptor-like nuclear imaging agents for hepatocellular carcinoma].
abstract: Hepatocellular carcinoma (HCC) commonly presents with high morbidity and mortality, and early staging diagnosis and timely treatment is pivotal to prolonging patients' survival time. Compared with traditional morphological imaging methods such as ultrasound, computed tomography (CT), and magnetic resonance imaging (MRI), functional imaging methods like single-photon emission computed tomography (SPECT) and positron emission tomography (PET) are playing an increasingly important role in the early diagnosis, efficacy assessment, prognostic evaluation, and treatment planning for HCC, thanks to their higher sensitivity at a molecular level by using various radiopharmaceuticals.
authors: Department of Nuclear Medicine, Zhongshan Hospital, Fudan University; Shanghai Institute of Medical Imaging, Shanghai 200032, China.
authors: Y L
authors: YL
authors: Li
authors: G B
authors: GB
authors: Liu
authors: D F
authors: DF
authors: Cheng
authors: H C
authors: HC
authors: Shi
mesh_terms: D006528:Carcinoma, Hepatocellular / Q000000981:diagnostic imaging*; D006801:Humans; D008113:Liver Neoplasms / Q000000981:diagnostic imaging*; D008279:Magnetic Resonance Imaging; D049268:Positron-Emission Tomography; D011237:Predictive Value of Tests; D011379:Prognosis; D019275:Radiopharmaceuticals / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D015899:Tomography, Emission-Computed, Single-Photon; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome; D014463:Ultrasonography
chemical_list: D019275:Radiopharmaceuticals